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Abstract 
Heparins are are sulfated polysaccharides that have tremendous clinical importance as 
anticoagulant drugs. Monitoring of heparin blood levels can improve patient safety. In clinical 
practice, heparins are monitored indirectly by their inhibtory effect on coagulation proteases. 
Drawbacks of these established methods have stimulated the development of simple direct 
detection methods with cationic dyes that change absorbance or fluorescence upon binding 
of polyanionic heparin. Very few such dyes or assay kits, however, are commercially and 
widely available to a broad community of researchers and clinicians. This study compares 
the performance of three commercial dyes for the direct quantification of unfractionated 
heparin and the widely used low-molecular-weight heparin enoxaparin. Two traditional 
metachromatic dyes, Azure A and Toluidine Blue, and the more recently developed 
fluorescent dye Heparin Red were applied in a mix-and-read microplate assay to the same 
heparin-spiked human plasma samples. In the clinically most relevant concentration range 
below 1 IU (international units) per mL, only Heparin Red is a useful tool for the 
determination of both heparins. Heparin Red is at least 9 times more sensitive than the 
metachromatic dyes which can not reliably quantify the heparins in this concentration range. 
Unfractionated heparin levels between 2 and 10 IU per mL can be determined by all dyes, 
Heparin Red being the most sensitive.     
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Introduction 
Heparins are widely used clinical anticoagulants, about one billion doses are applied each 
year.  Heparin is a linear, polydisperse polysaccharide consisting of disaccharide repeating 
units (scheme 1) and has a high negative charge density due to sulfation. Unfractionated 
heparin (mean molecular weight between 13000 and 15000) is clinically applied since the 
1930s. For many indications, there has been a trend towards use of fractionated low 
molecular weight heparins (mean molecular weight between 4000 and 7000), manufactured 
by partial depolymerisation of unfractionated heparin. Low-molecular-weight heparins, such 
as the most widely used enoxaparin, have lower side effects and a more favourable 
pharmacokinetics. Safe and effective use of heparins requires maintaining a delicate balance 
- dosing low enough to minimize the risk of bleeding, yet high enough to treat or prevent 
thrombosis. Measurement of activated partial thromboplastin time aPTT  (the ability to delay 
clotting) and chromogenic anti-factor Xa assay (inhibition of a specific blood coagulation 
factor), are the currently accepted practice for laboratory monitoring of unfractionated and 
low molecular weight heparins, respectively, in patients’ blood. Accurate laboratory 
monitoring has proven to be difficult to achieve. [1-3] Comparability between commcercially 
available anti-factor Xa assays is poor.  
 
 
Scheme 1. Structure of the major repeating disaccharide unit of heparin.   
 
The drawbacks of the established indirect assays have stimulated the development of direct 
optical detection methods that rely on the color or fluorescence change of cationic dyes upon 
binding to polyanionic heparin [4]. Only few such dyes or assay kits, however, are 
commercially and widely available to reserachers and clinicians. 
   
This study compares the performance of three commercial dyes (assays, respectively) for 
direct heparin detection in human plasma: The more recently developed fluorescent dye 
Heparin Red and the traditional metachromatic dyes Azure A and Toluidine Blue. 
  
Heparin Red is a polyamine-functionalized, red-fluorescent perylene diimide (scheme 2). It 
forms a supramolecular complex with polyanionic polysaccharides in which aggregation of 
dye molecules results in contact quenching of fluorescence (scheme 3). [5] Strong binding of 
 
the polycationic probe to polyanionic heparin appears to be controlled by both electrostatic 
and aromatic pi-stacking interactions, with formation of charge-neutral aggrgeates. [6] The 
commercial Heparin Red Kit has been applied to the quantification in the low µg/mL range of 
unfractionated heparin [7], the low molecular weight heparins enoxaparin [7] and dalteparin 
[8], heparin octa- and decasacchairides [7], chemically modified heparins [7], heparan sulfate 
[9], fucoidans [10], carrageenan [8], ulvan [8],  dextran sulfate [8] and sulfated hyaluronic 
acid [8] in human plasma. Heparin Red is used in several drug development projects for 
pharmacokinetic studies of non-anticoagulant heparins.[11]   
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Scheme 2. Molecular structures of the polycationic, fluorescent probe Heparin Red, and the 
monocationic, metachromatic dyes Azure A and Toluidine Blue. 
 
 
 
Scheme 3. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of polyanionic polysaccharides.     
 
Azure A and Toluidine Blue (scheme 2) are blue, monocationic dyes of the thiazine family. 
These dyes show metachromatic behaviour in the presence of sulfated polysaccharides [12, 
 
13], they change color when associating with the target. Applications include staining of 
sulfated polysaccharides in tissue and (after electrophoresis) in gels, and direct detection in 
solution if intereference from sample matrix is low. A structurally related thiazine dye, 
dimethylmethylene blue, is the major component of a commercial kit (Blyscan) that is widely 
used for sulfated polysaccharide detection. The Blyscan multistep protocol [14] is based on 
the intentional precipitation of the dye-polysaccharide complex, followed by isolation of the 
precipitate, re-dissolution of the complex at high salt concentration and colorimetric 
quantification of the dye component.  A similar precipitation- redissolution protocol is followed 
for sulfated polysaccharide quantification with Alcian Blue [15, 16], a tetracationic copper-
phthalocyanine derivative, although this dye does not display metachromatic behaviour. The 
uses and limitations of these “blue dyes” have been discussed in several reviews and 
research papers [17-20]. In blood plasma, strong matrix interference complicates the 
detection of heparin. Only few protocols for the direct determination of unfractionated heparin 
in plasma or serum samples have been described in the literature.[21-23]   
 
The present study compares the performance and sensitivity of the three commercial dyes 
Heparin Red, Azure A and Toluidine Blue, using the same heparin-spiked plasma samples 
and a convenient, mix-and-read microplate protocol.    
 
 
Materials and Methods 
Instrumentation 
Absorbance measurements 
Absorbance at 620 or 630 nm was measured with a microplate reader Biotek, EON, (Biotek  
Instruments, Winooski, VT, USA) using Gen 5 software, version 2.06.10 for data recording. 
 
Fluorescence measurements 
Fluorescence (Heparin Red® assay) was measured with a microplate reader Biotek Synergy 
Mx (Biotek  Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 
nm,  spectral band width 13.5 nm, read height of 8 mm. 
 
Microplates 
For absorbance measurements, 96-well microplates, polystyrene, costar Item No 3474, were 
purchased from Corning Incorporated (NY, USA). For fluorescence measurements (Heparin 
Red® assay) 96 well microplates, polystyrene,  Item No 655076, were purchased from 
Greiner Bio-One GmbH, Frickenhausen.  
 
 
Reagents 
 
Dyes and Kits 
The Heparin Red® Kit  was a gift from Redprobes UG, Münster, Germany [24]. Kit 
components: Heparin Red solution, Product No HR001, Lot 01-004, and Enhancer Solution, 
Product No ES001, Lot 006. Azure A (chloride; dye content 70%) was provided by Sigma-
Aldrich GmbH Steinheim (product number 861049, Lot Nr MKBW1530V). Toluidine Blue 
(tetrachlorozincate) was provided by Sigma-Aldrich GmbH Steinheim (product number 
89640, Lot Nr. BCBR0169V.  
Heparins 
Unfractionated heparin sodium salt from porcine intestine mucosa (“heparin”), was sourced 
as a solid from Sigma-Aldrich GmbH, Steinheim (product number H5515, Lot SLBK0235V, 
indicated potency 210 IU/mg). We are grateful to Apotheke des Universitätsklinikums 
Heidelberg for the gift of enoxaparin (Clexane® 20 mg, Sanofi, solution 10000 IU/mL). 
 
Plasma 
Pooled human plasma was prepared by mixing equal volumes of ten single-donor citrated 
plasmas of healthy individuals, provided by the Blood Bank of the Institute for Clinical 
Transfusion Medicine and Cell Therapy Heidelberg (IKTZ). Plasma as well as heparin spiked 
plasma samples were stored at -20°C. 
 
Other 
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328. 10% Pluronic® F-68 non-ionic surfactant Item No. 24040032 was purchased 
from Thermo Fisher Scientific. Dulbecco’s Phosphate buffered saline (DPBS) Item No. 
14190-094 was purchased from Thermo Fisher Scientific. 
 
 
Methods 
 
Heparin Red® Kit 
For determination of heparin concentrations in the range <1 IU/mL in in plasma samples, the 
protocol of the provider for a 96-well microplate assay was followed. A mixture of 100 µL 
Heparin Red solution and 9 mL Enhancer solution was freshly prepared. 20 µL of the heparin 
spiked plasma sample was pipetted into a microplate well, followed by 80 µl of the Heparin 
Red – Enhancer mixture. The microplate was introduced in the fluorescence reader and 
 
shaken for 3 minutes, using plate shaking function of the reader (setting “high”), followed by 
fluorescence measurement within 1 minute. For determination of heparin concentrations up 
to 10 IU/mL in plasma samples, a mixture of 600 µL Heparin Red solution and 9 mL 
Enhancer solution was freshly prepared. Otherwise, the protocol was followed as described 
above.  
 
Azure A assay, method 1 
For determination of heparin concentrations in plasma samples, the literature protocol [21] 
for a “4-units assay” was followed, but heparin from porcine mucosa (instead of bovine lung 
heparin) was used and the protocol adapted for detection in 96-well microplates. A solution 
of Azure A in water (8 mg / 100 mL, c = 80µg/mL) was freshly prepared. 50 µL of the heparin 
spiked plasma sample was pipetted into a microplate well, followed by 50 µl of the Azure A 
solution. The microplate was immediately introduced in the absorbance reader and shaken 
for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by 
absorbance measurement within 1 minute.  
 
Azure A assay, method 1a 
For determination of heparin concentrations in plasma samples, the literature protocol [21] 
for a “10-units assay” was followed, but heparin from porcine mucosa (instead of bovine lung 
heparin) was used and the protocol adapted for detection in 96-well microplates. A solution 
of Azure A in water (1 mg / 100 mL, c = 10µg/mL) was freshly prepared. 10 µL of the heparin 
spiked plasma sample was pipetted into a microplate well, followed by 200 µl of the Azure A 
solution. The microplate was immediately introduced in the absorbance reader and shaken 
for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by 
absorbance measurement within 1 minute.  
 
Azure A assay, method 2 
For determination of heparin concentrations in plasma samples, a protocol described in a 
patent [22] was followed, but the commercial Azure A sample was not purified, human 
plasma was used (instaed of horse serum) and the protocol adapted for detection in 96-well 
microplates. A solution of Azure A (14.6 µg / mL) in 1% aqueous Pluronic (commercial 
product was diluted 10-fold with water) was freshly prepared. 10 µL of the heparin spiked 
plasma sample was pipetted into a microplate well, followed by 100 µl of the Azure A 
solution. The microplate was immediately introduced in the absorbance reader and shaken 
for 1 minute, using the plate shaking function of the reader (setting 567 cpm), followed by 
absorbance measurement within 1 minute. 
 
 
Toluidine Blue assay 
For determination of heparin concentrations in plasma samples, a literature protocol [23] was 
followed, but sodium heparin (instead of lithium heparin) and citrated human plasma (instead 
of EDTA human plasma) were used and the protocol adapted for detection in 96-well 
microplates. A solution of Toluidine Blue (100 µg / mL) in phosphate buffered saline (DPBS) 
was freshly prepared. 50 µL of the heparin spiked plasma sample was pipetted into a 
microplate well, followed by 50 µl of the Toluidine Blue solution. The microplate was 
immediately introduced in the absorbance reader and shaken for 1 minute, using the plate 
shaking function of the reader (setting 567 cpm), followed by absorbance measurement 
within 1 minute. 
 
Preparation of spiked plasma samples 
Plasma samples containing defined concentrations of heparins were prepared as follows: 
Aqueous solutions (10 vol%) of unfractionated heparin and enoxaparin, respectively, were 
added too pooled human plasma to achieve a concentration of 10 IU/mL. Heparin 
concentrations required for the detections were adjusted by further dilution of this 10 IU/mL 
stock solution with the same plasma. The spiked plasma samples were stored at -20°C and 
thawed at room temperature before use. 
 
Data analysis 
Data were analyzed using Excel (Microsoft Office 10). Linear regression “through origin” ( 
with y-intercept set to 1) was applied to the response curves in figure 2.  Coefficients of 
determination (R2) in table 1 were determined by linear regression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion 
While the Heparin Red, Azure A and Toluidine Blue assay actually determine a mass 
concentration of heparin (the “chemical” heparin) rather than a biological activity, we refere in 
this work to IU (international units) of heparin for better comparability with published data for 
the metachromatic dyes and clinically relevant heparin levels. The heparin batch used in this 
work had a potency of 210 IU/mg solid, i.e. 1 IU corresponds to 4,8 µg.  
The Heparin Red Kit was applied either as suggested by the protocol of the supplier, or 
adapted to higher heparin levels by using a higher concentrations of the dye (see “Materials 
and Methods” for details). For Azure A, we compared three different published protocols 
(method 1, 1a and 2) for heparin detection. In method 1 and 1a [21], an aqueous solution of 
the dye and the heparin containing plasma sample are mixed in either a 1:1 ratio (for heparin 
levels up to 4 IU/mL, method 1) or 1:9 ratio (for heparin levels up to 10 IU/mL, method 1a) in 
a cuvette and dye absorbance at 620 nm is measured with a photometer. Azure A, Method 2, 
was described in a patent [22]: an aqueous solution of the dye containing an anionic 
surfactant is mixed with a heparin containing sample of horse serum at a 10:1 ratio in a 
cuvette and the absorbance spectrum recorded with a photometer. A protocol using 
Toluidine Blue [23] suggests mixing of equal amounts of a dye solution in phosphate buffered 
saline and heparin containing plasma sample, followed by absorbance readout with a 
Nanodrop photometer at 630 nm.  
We adapted these protocols for microplates, i.e. dye solution and plasma sample were mixed 
in 96-well microplate wells and absorbance read with a microplate reader. For Azure A, 
method 2, the serum was replaced by a human plasma sample. The linear relation between 
dye concentration and absorbance readout of the plate reader in the relevant concentration 
range of Azure A is shown in figure 1. Solutions of Toluidine Blue in the range 0-40 µg/mL 
also displayed good linearity of absorbance (data not shown).   
  
Figure 1. Linear relation between Azure A mass concentration (range 0-40 µg/mL) and 620 nm 
absorbance of aqueous solutions of Azure A. Absorbance (arbitrary units) measured in microplate 
wells (sample volume 100 µL) with a microplate reader.   
 
Quantification of unfractionated heparin and enoxaparin at concentrations <1 IU/mL in 
human plasma 
In the vast majority of clinical heparin applications, the recommended plasma level is < 1 
IU/mL. More precisely, the range for therapeutic dosing is 0.3 – 0.7 IU/mL for unfractionated 
heparin and  0.5 – 1.0 IU/mL for enoxaparin, and for prophylactic doses 0.1 – 0.4 IU/mL for 
heparin and 0.2 – 0.4 IU/mL for enoxaparin. Therefore, the first series of heparin 
determinations (figure 2) focuses on concentrations < 1 IU/mL plasma. The fact that all dyes 
respond to heparin by a decrease of optical signal (fluorescence at 610 nm or absorbance at 
about 620 nm, respectively) facilitates the comparison of their performance in heparin 
detection. The normalized response of Heparin Red, Azure A (method 1 and 2) and Toluidine 
Blue to the same heparin spiked human plasma samples is shown in figure 2. 
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Figure 2. Normalized heparin dose response curves of the four assays Heparin Red, Azure A (M1 = 
method 1, M2 = method 2), and Toluidine Blue. “Optical signal” refers in case of Heparin Red to 610 
nm fluorescence, for Azure A assays to 620 nm absorbance and for Toluidine Blue assay to 630 nm 
absorbance. Heparin in IU/mL refers to the concentration in spiked pooled normal plasma samples. 
Manually performed microplate assays, as described in the “Materials and Methods” section. Averages 
of duplicate determinations.  
While the fluorescence signal of Heparin Red displays a strong  decrease in the range 0-1 
IU/mL, the other dyes show only poor response. Heparin levels <1 IU/mL have actually not 
been measured by the literature protocols for Azure A, method 1, and Toluidine Blue. The 
lowest measured plasma concentrations were 1 IU/mL for Azure A, method 1 [21] and 1.7 
IU/mL for Toluidine Blue [23]. Azure A, method 2, described in a patent [22], claims a 
detection limit of 0.1 IU/mL heparin in horse serum, derived from changes in the area under 
the absorption spectra.  In our hands, however, this protocol has the poorest detection limit 
and linearity (table 1) of all methods when applied to heparin-containing plasma samples in a 
microplate, independent of how the optical signal change is monitored.   
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The detection and quantification limits of the assays (table 1) were determined based on 
signal-to-noise [25], by relating extrapolated response (linear regression “through origin”, y 
intercept set to 1) to the standard deviation of blank samples (σblank) without heparin. The limit 
of detection (LOD) was calculated as LOD = 3 σblank / S (S= slope of response curve, see 
figure 1) and the limit of quantification as LOQ = 10 σblank / S.  
 
Assay Heparin Red Azure A M1 Azure A M2 Toluidine Blue 
σblank (n=8) 0.014 0.013 0.020 0.025 
r2 0.98 0.94 0.03 0.17 
LOD (IU/mL)  0.06 0.54 0.94 0.85 
LOQ (IU/mL) 0.20 1.8 3.1 2.8 
 
Table 1. σblank, coefficient of determination (r2), limit of detection (LOD) and limit of quantification 
(LOQ) of heparin in human plasma  by the four assays Heparin Red, Azur A M1, Azure A M2 and 
Toluidine Blue. σblank is the standard deviation of the normalized optical signal of a heparin-free dye-
plasma mixture. r2 is the coefficient of determination obtained from linear regression (figure 2).  LOD = 
3 σblank / S (S= slope of response curve, see figure 2). LOQ = 10 σblank / S. 
When compared on the basis of optical signal change (figure 2), the Heparin Red assay is at 
least 8 times more sensitive to heparin than the metachromatic dyes. When compared on the 
basis of detection and quantification limits (table 1), Heparin Red is at least 9 times more 
sensitive than the metachromatic dyes. Quantification limits of the latter lie outside the 0-1 
IU/mL concentration range. In addition, the Heparin Red assay has the best linear correlation 
(table 1) between heparin concentration and optical signal.  
Response of the assays to the low molewcular weight heparin enoxaparin (figure 3) follows 
similar trends as observed for unfractionated heparin. The decrease of optical signals is 
more pronounced since in the heparin and enoxaparin solutions of the same potency 
(expressed in IU/mL), the mass concentration of enoxaparin is significantly higher, and the 
dye assays respond to mass concentration rather than potency (compare reference [7]).   
 
 
  
Figure 3. Normalized enoxaparin dose response curves of the four assays Heparin Red, Azure A (M1 
= method 1, M2 = method 2), and Toluidine Blue. “Optical signal” refers in case of Heparin Red to 610 
nm fluorescence, for Azure A assays to 620 nm absorbance and for Toluidine Blue assay to 630 nm 
absorbance. Enoxaparin in IU/mL refers to the concentration in spiked pooled normal plasma samples. 
Manually performed microplate assay, as described in the “Materials and Methods” section. Averages 
of duplicate determinations. 
Quantification of unfractionated heparin at concentration up to 10 IU/mL in human 
plasma 
In specific clinical situations such as cardiopulmonary bypass surgery, application of 
unfractionated heparin concentrations at blood levels up to 10 IU mL is adequate. The 
Heparin Red assay is readily adapted to this concentration range (figure 4) by increasing the 
dye concentration, see “Materials and Methods” for details. The metachromatic dye assays 
are also suitable for heparin quantification in this extended concentration range, although 
their response is more than two-fold weaker compared with Heparin Red. A good match with 
literature data is observed for Azure A, method 1 (2 and 4 IU/mL heparin), while our protocol 
provides a weaker response for Azure A, method 1a and Azure A, method 2, and a stronger 
response for the Toluidine Blue assay. This could be related to different heparins and 
matrices used in the literature reported assays (see “Materials and Methods” for details).   
0
0.2
0.4
0.6
0.8
1
1.2
0 0.2 0.4 0.6 0.8 1 1.2
no
rm
al
is
ed
 op
tic
al
 sig
na
l
Enoxaparin (IU/mL)
Azure A M1
Azure A M2
Toluidine Blue
Heparin Red
  
Figure 4. Normalized heparin dose response curves of the five assays Heparin Red, Azure A (M1 = 
method 1, M1a = method 1a, M2 = method 2), and Toluidine Blue. “Optical signal” refers in case of 
Heparin Red to 610 nm fluorescence, for Azure A assays to 620 nm absorbance and for Toluidine 
Blue assay to 630 nm absorbance. Heparin in IU/mL refers to the concentration in spiked pooled 
normal plasma samples. Manually performed microplate assay, as described in the “Materials and 
Methods” section. Averages of duplicate determinations. 
 
Conclusion 
Heparins are widely used anticoagulant drugs. In clinical practice, blood levels of heparins 
are monitored indirectly by their effect on coagulation factors, although accurate laboratory 
monitoring has proven to be difficult to achieve.  Direct detection of heparins by cationic dyes 
that change absorbance or fluorescence upon binding of polyanionic heparin offers an 
alternative tool for quantification. Only few such dyes or assay kits, however, are 
commercially and widely available to researchers and clinicians. The present study 
compares the performance and sensitivity of three commercial dyes for the direct 
quantification of heparins in human plasma: two traditional metachromatic dyes, Azure A and 
Toluidine Blue, and the more recently developed fluorescent dye Heparin Red. In the 
clinically most relevant concentration range below 1 IU per mL, only Heparin Red is a useful 
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tool for determination of heparins. It is at least 9 times more sensitive than the metachromatic 
dyes which can not be reliably quantify the heparins in this concentration range if the limit of 
quantification is defined as 10 σblank / S (σblank: standard deviation of blank; S: slope of 
response curve). Higher heparin levels of 2 -10 IU/mL can be determined by all dyes, 
Heparin Red being the most sensitive.     
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